The diligent work that pathologists do in labs every day has a significant impact on patient treatment and care – particularly in cancer care, where pathology plays a crucial role in diagnostics and cancer staging. In fact, it’s estimated that 70% of important medical decisions affecting patients’ lives involve laboratory or pathology tests.
Siemens Healthineers expands its Enterprise Imaging offering with Proscia’s Concentriq Dx platform for digital pathology PHILADELPHIA – March 16, 2022 - Proscia®, the leader in digital and computational pathology solutions, today announced a multi-year OEM agreement with Siemens Healthineers. Under the agreement, Siemens Healthineers will expand its Enterprise Imaging offering towards the global digital pathology market using Proscia’s Concentriq® [...]
Proscia®, the leader in digital and computational pathology solutions, and Hamamatsu Photonics K.K., a leading provider of whole slide imaging systems, today announced a collaboration to accelerate digital pathology adoption at an enterprise scale.
Source BioScience completes £18.5m strategic acquisition of LDPath Ltd Completes £18.5m strategic acquisition of LDPath Ltd Creates the largest and most technically advanced private provider of cellular and digital pathology services in the UK Digitises diagnostic pathways, leading to faster diagnosis and helping clear backlog of elective surgeries as a result of the pandemic Provides access [...]
Partnership to provide access to Flagship’s AI-aided software for quantifying PD-L1 IHC stains across various tissue typesNEW YORK & BROOMFIELD, Colo.–(BUSINESS WIRE)–Paige,the global leader in AI-based diagnostic software in pathology, and Flagship Biosciences, a leader in data-centric pathology and tissue analysis, today announced a partnership to provide access to Flagship’s TissueInsight™, an AI-aided diagnostics software that quantifies PD-L1 expression in immunohistochemistry tissue samples, directly through the Paige Platform.For rapid and precise cancer care, pathologists and oncologists need dependable diagnostic testing to connect patients to individualized immuno-oncology therapies. TissueInsight™ is a clinical diagnostic immuno-oncology service which provides Clinical Laboratory Improvement Amendments (CLIA)-reportable PD-L1 results along with data about the tumor microenvironment (TME), such as information about tumor infiltrating lymphocytes (TILs) and macrophages. TissueInsight™ automatically reads a tissue slide and provides rapid, data-rich tissue interpretations and removes the inherent variability of subjective manual tissue scoring.“By enabling pathologists to access Flagship’s PD-L1 analysis tool directly within the Paige Platform, we are providing pathologists and oncologists quicker access to biomarker testing results that will inform treatment planning,” said Andy Moye, Ph.D., CEO at Paige. “This partnership can make it easier and more efficient for pathologists to quantify a prominent immunotherapy biomarker and can help improve patient care.”TissueInsight™ will be available directly in the FullFocus® platform, enabling a complete and seamless digital pathology workflow. “TissueInsight’s integration with Paige’s platform will truly provide a diagnostic service unmatched in the industry,” said Trevor Johnson, CEO at Flagship Biosciences. “TissueInsight™ is the only turnkey digital pathology solution for IHC scoring and we look forward to partnering with Paige to successfully integrate, deploy, and promote adoption of our innovative technology.”“Immunohistochemistry scoring of PD-L1 has traditionally been a time-consuming, manual process that is subject to variability between pathologists,” said David Klimstra, M.D., Founder and Chief Medical Officer at Paige. “TissueInsight augments our native Paige capabilities by providing an easy-to-use and accurate software that produces more information of clinical value than can be generated manually.”About Flagship BiosciencesFounded in 2009 and headquartered in Broomfield, Colorado, Flagship Biosciences, Inc. is a technology-driven tissue analysis services company delivering the most accurate and informative data available. We are revolutionizing tissue analysis to improve drug development and diagnostics using the power of AI with a consultative approach. Our services and technology dramatically improve on the data and interpretation from traditional pathology methods, eliminating variability associated with typical tissue assessments, and bringing new insights to tissue analysis results. We provide expert scientific consultation for every client. Our team interprets results, contextualizes tissue biology, and identifies the best course for success. https://flagshipbio.com/SOURCE: Paige
Tribun Health (Formerly Tribvn Healthcare) today announced it has won the prestigious customer satisfaction award "Best in KLAS" for Digital Pathology for 2022 in Europe. KLAS Research has been providing accurate, honest, and impartial insights for the healthcare IT (HIT) industry since 1996.
Introduction: Philips explains how digital pathology accelerates the pathway to personalized cancer care Digital pathology offers efficiency and enhanced collaboration Growing caseloads, fewer pathologists workflow challenges and the need for timely, precise diagnosis are driving the adoption of digital pathology. Digital pathology redefines diagnostic workflows with high-resolution imaging, the ability to integrate artificial intelligence (AI) [...]
Scarring alopecias—also referred to as primary cicatricial alopecias—are a diverse group of rare disorders that cause irreversible patchy hair loss. There are different types of scarring alopecias, making differential diagnosis challenging.
The realization of the diagnostic, prognostic, and predictive value of tissue biomarkers has led to an unprecedented rate of development of assays to detect and quantify tissue biomarkers. This rapid increase in the number of quantitative image analysis methods for tissue biomarkers with potential clinical applications has raised various regulatory issues and necessitates the establishment of appropriate regulatory frameworks.
Orchard Software announced the release of its newest product—Orchard® Enterprise Pathology™—a cloud-based Laboratory Information System designed to enable pathology laboratories to continue to expand their business, quickly adapt to change, and be an integral part of an interoperable healthcare system.
